Ikena Oncology (IKNA) Q3 2025 earnings summary

Executive summary

• Completed a reverse recapitalization merger with Ikena Oncology, Inc. on July 25, 2025, and a $75M private placement, resulting in a new public entity focused on immunological, autoimmune, and inflammatory diseases, with $142.6M in cash and marketable securities as of September 30, 2025.

• Strengthened leadership with new CEO, CSO, CTO, and independent director appointments.

• Lead asset IMG-007, a non-depleting anti-OX40 monoclonal antibody, is the sole clinical-stage product after divestiture of non-OX40 assets, advancing in atopic dermatitis and alopecia areata.

• Initiated a Phase 2b study for IMG-007 in atopic dermatitis, with topline data expected in 2027.

Financial highlights

• Net loss of $24.8 million for Q3 2025, up from $3.2 million in the prior year, with $142.6 million in cash, cash equivalents, and marketable securities as of September 30, 2025.

• Research and development expenses were $15.6 million for Q3 2025, up 300% year-over-year, mainly due to increased stock-based compensation and clinical trial costs.

• General and administrative expenses rose to $11.0 million for Q3 2025, up 568% year-over-year, reflecting higher stock-based compensation and professional services.

• Net cash used in operating activities was $40.6 million for the nine months ended September 30, 2025.

Outlook and guidance

• Current cash position expected to fund operations for at least the next 12 months.

• Substantial additional funding will be required to advance IMG-007 and any future product candidates through development and commercialization.

• Ongoing Phase 2b ADAPTIVE trial in atopic dermatitis continues with protocol amendment planned to optimize dosing and study design; topline data anticipated in 2027.

• Upcoming data presentations at ISDS 2025 to highlight IMG-007's activity in alopecia areata and atopic dermatitis.